Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
-
Field
-
a two-year Global Scientific Communications fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new
-
Science fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
Global Scientific Communications fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of
-
JSPS Grants-in-Aid. https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-23H00466/ https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-25K21806/ Scope of changes: Assignments may include reassignments
-
a two-year Global Patient Safety and Risk Management fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a
-
Affairs fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
Global Medical Affairs TTR fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative
-
Affairs fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with
-
a two-year Global Medical Affairs Early Assets fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole
-
at the intersection of academia and practice. For more information on D^3, please visit https://d3.harvard.edu/labs . D^3 is looking for candidates with diverse backgrounds and/or new perspectives. There are no